Photoreactive antibody binding domains accelerate antibody-based therapeutic development
Most standard approaches to preparing antibody conjugates suffer from non-quantitative, indiscriminate labeling. The value of introducing cargo at specific sites has become increasingly apparent. However, current site-specific labeling methods are not amenable to high-throughput screening and pose characterization challenges. This led Dr. Andrew Tsourkas, Professor and Undergraduate Chair of Bioengineering at the University of Pennsylvania, to develop photoreactive antibody binding domains (pAbBDs), enabling rapid, highly efficient, and site-specific labeling of full-length antibodies with essentially any cargo.
Dr. Tsourkas will describe how pAbBDs can accelerate the development of antibody-drug conjugates, allow for the exploration of new therapeutic paradigms such as T cell redirecting autoantibodies, and enable the cytosolic delivery of full-length antibodies that can target and inhibit the undruggable proteome.
Key learning objectives
- Photoreactive antibody binding domains enable the site-specific attachment of chemical and protein cargo to nearly any off-the-shelf antibody.
- xCELLigence Real-Time Cell Analysis allows for the high-throughput evaluation of antibody-based therapeutics, accelerating drug development.
- Simplification of antibody labeling can lead to the exploration of new therapeutic paradigms.
Who should attend?
Researchers and scientists in industry and academia, basic and translational antibody drug researchers, and drug discovery enthusiasts.
Certificate of attendance
All webinar participants can request a certificate of attendance, including a learning outcomes summary, for continuing education purposes.
Speakers
Dr. Andrew Tsourkas is a Professor and Undergraduate Chair of Bioengineering at the University of Pennsylvania. He received his Bachelor’s degree in Mechanical Engineering from Cornell University and his Ph.D. in Biomedical Engineering from the Georgia Tech/Emory University joint Ph.D. program. He conducted a post-doctoral fellowship in the Department of Radiology at Harvard University before joining the Department of Bioengineering at the University of Pennsylvania in 2004. Dr. Tsourkas is the Co-Director of the Center for Targeted Therapeutics and Translational Nanomedicine. Dr. Tsourkas founded AlphaThera, Inc. in 2016, a biotechnology company that develops reagents for the site-specific labeling of antibodies.
Moderator
